Format

Send to

Choose Destination
Intern Med. 2018 Sep 1;57(17):2527-2531. doi: 10.2169/internalmedicine.0126-17. Epub 2018 Jun 6.

The Effect of Everolimus on Refractory Hypoglycemia in a Patient with Inoperable Metastatic Insulinoma Evaluated by Continuous Glucose Monitoring.

Author information

1
Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University Graduate School of Medicine, Japan.
2
Department of Gastroenterology and Hepatology, Hokkaido University Graduate School of Medicine, Japan.
3
Department of Cancer Center, Hokkaido University Hospital, Japan.
4
Department of Surgical Pathology, Hokkaido University Hospital, Japan.

Abstract

An 84-year-old Japanese woman with metastatic insulinoma suffered from frequent hypoglycemic events. Continuous glucose monitoring (CGM) confirmed severe and frequent symptomatic/asymptomatic hypoglycemia. After the initiation of everolimus treatment, the hypoglycemic events were rapidly eliminated. CGM revealed that her blood glucose levels were maintained without hypoglycemia throughout the day. Furthermore, everolimus reduced the duration of time above the upper limit (>180 mg/dL) along with the standard deviation and mean amplitude of glycemic excursions. This case shows the potential effects of everolimus on hypoglycemia and glycemic control in a patient with inoperable metastatic insulinoma evaluated by CGM.

KEYWORDS:

continuous glucose monitoring; everolimus; hypoglycemia

Supplemental Content

Full text links

Icon for J-STAGE, Japan Science and Technology Information Aggregator, Electronic Icon for PubMed Central
Loading ...
Support Center